Until such evidence is available for retatrutide, therapies with established cardiovascular and renal benefitssuch as semaglutide, supported by SUSTAIN-6 [5] and FLOW [57] trials in people with T2D, and the SELECT trial [58] in people with obesity - should be prioritised in populations with existing cardio-renal disease
Age, sex, baseline BMI, and existing liver or gallbladder ultrasound findings all shape your individualized risk profile and treatment plan
However, Tf protects against such damage by binding to iron 42,43
It is a new finding in the incretin class
If youve already used retatrutide bought online, see your GP, particularly if youve experienced side effects